IL272064A - Binding proteins 1 - Google Patents
Binding proteins 1Info
- Publication number
- IL272064A IL272064A IL272064A IL27206420A IL272064A IL 272064 A IL272064 A IL 272064A IL 272064 A IL272064 A IL 272064A IL 27206420 A IL27206420 A IL 27206420A IL 272064 A IL272064 A IL 272064A
- Authority
- IL
- Israel
- Prior art keywords
- binding proteins
- proteins
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533546P | 2017-07-17 | 2017-07-17 | |
| US201762596694P | 2017-12-08 | 2017-12-08 | |
| PCT/US2018/042532 WO2019018426A1 (en) | 2017-07-17 | 2018-07-17 | BINDING PROTEINS 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL272064A true IL272064A (en) | 2020-03-31 |
Family
ID=65015294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272064A IL272064A (en) | 2017-07-17 | 2020-01-15 | Binding proteins 1 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US11613590B2 (enExample) |
| EP (1) | EP3655432A4 (enExample) |
| JP (2) | JP7690285B2 (enExample) |
| CN (1) | CN111094338A (enExample) |
| AU (1) | AU2018302110B2 (enExample) |
| CA (2) | CA3300582A1 (enExample) |
| IL (1) | IL272064A (enExample) |
| WO (2) | WO2019018426A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2744840T3 (es) | 2011-04-01 | 2020-02-26 | Univ Yale | Anticuerpos anti-ADN que penetran en las células y usos de los mismos para inhibir la reparación del ADN |
| US12486318B2 (en) | 2016-06-15 | 2025-12-02 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| WO2017218825A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| WO2019152806A1 (en) * | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for enhancing nuclear translocation |
| US20210340279A1 (en) * | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
| US12485180B2 (en) | 2019-08-30 | 2025-12-02 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| IL301014A (en) | 2020-08-31 | 2023-05-01 | Univ Yale | Compositions and methods for delivery of nucleic acids to cells |
| CN117295753A (zh) | 2020-12-04 | 2023-12-26 | 基那奥生物公司 | 用于将核酸递送到细胞的组合物和方法 |
| IL305515A (en) | 2021-03-03 | 2023-10-01 | Univ Yale | Preparations and methods for the treatment of skeletal muscle disease |
| US20240226311A1 (en) * | 2021-05-25 | 2024-07-11 | Transmab Pty Ltd | Improved immunoglobulin II |
| US20240226316A1 (en) * | 2021-05-25 | 2024-07-11 | Transmab Pty Ltd | Improved immunoglobulin I |
| IL309662A (en) | 2021-07-02 | 2024-02-01 | Univ Yale | Compositions and methods for treating cancers |
| EP4395832A1 (en) | 2021-08-31 | 2024-07-10 | Yale University | Compositions and methods for treating cancers |
| US20250051406A1 (en) * | 2021-12-15 | 2025-02-13 | The Trustees Of Indiana University | Cell targeting compositions and methods |
| US20250170259A1 (en) | 2022-03-03 | 2025-05-29 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| JP2025507840A (ja) * | 2022-03-03 | 2025-03-21 | イエール ユニバーシティ | ヒト化３ｅ１０抗体、そのバリアント、及び抗原結合断片 |
| US20250161484A1 (en) | 2022-03-03 | 2025-05-22 | Yale University | Compositions and methods for treating disease |
| EP4584292A1 (en) | 2022-09-09 | 2025-07-16 | Yale University | Proteolysis targeting antibodies and methods of use thereof |
| CN120787163A (zh) | 2022-12-27 | 2025-10-14 | 耶鲁大学 | 抗体药物缀合物 |
| EP4655007A1 (en) | 2023-01-23 | 2025-12-03 | Yale University | Antibody oligonucleotide conjugates |
| EP4683674A1 (en) | 2023-03-23 | 2026-01-28 | Yale University | Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping |
| WO2025049905A1 (en) | 2023-09-01 | 2025-03-06 | Gennao Bio, Inc. | Dnase co-expression in host cells |
| WO2025090121A1 (en) * | 2023-10-27 | 2025-05-01 | Yale University | Conjugate and methods of treatment |
| WO2025097000A1 (en) | 2023-11-01 | 2025-05-08 | Yale University | Antibody-based methods for treating polycystic kidney disease |
| CN117924516B (zh) * | 2024-01-02 | 2025-07-01 | 河北神宇生物技术有限公司 | 一种提高adc药物疗效的重组蛋白及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0615662D0 (en) | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| CA2936102A1 (en) * | 2014-01-13 | 2015-07-16 | Valerion Therapeutics, Llc | Internalizing moieties |
| WO2015134607A1 (en) | 2014-03-04 | 2015-09-11 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations |
| WO2015192092A1 (en) * | 2014-06-13 | 2015-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
| EP3186278A4 (en) * | 2014-08-27 | 2018-04-04 | Valerion Therapeutics, LLC | Internalizing moieties for treatment of cancer |
| JP2017534571A (ja) | 2014-08-28 | 2017-11-24 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 抗体３ｅ１０の多価フラグメントおよびその使用方法 |
| US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
-
2018
- 2018-07-17 EP EP18835802.2A patent/EP3655432A4/en active Pending
- 2018-07-17 WO PCT/US2018/042532 patent/WO2019018426A1/en not_active Ceased
- 2018-07-17 CA CA3300582A patent/CA3300582A1/en active Pending
- 2018-07-17 CA CA3070252A patent/CA3070252A1/en active Pending
- 2018-07-17 US US16/631,418 patent/US11613590B2/en active Active
- 2018-07-17 CN CN201880054249.7A patent/CN111094338A/zh active Pending
- 2018-07-17 US US16/631,421 patent/US20200216568A1/en not_active Abandoned
- 2018-07-17 AU AU2018302110A patent/AU2018302110B2/en active Active
- 2018-07-17 JP JP2020502992A patent/JP7690285B2/ja active Active
- 2018-07-17 WO PCT/US2018/042534 patent/WO2019018428A1/en not_active Ceased
-
2020
- 2020-01-15 IL IL272064A patent/IL272064A/en unknown
-
2022
- 2022-12-20 US US18/069,124 patent/US20240052063A1/en active Pending
-
2023
- 2023-02-03 US US18/164,444 patent/US12312417B2/en active Active
- 2023-04-12 JP JP2023065086A patent/JP2023083385A/ja active Pending
-
2025
- 2025-04-22 US US19/186,381 patent/US20250376540A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023083385A (ja) | 2023-06-15 |
| EP3655432A4 (en) | 2021-04-14 |
| AU2018302110B2 (en) | 2024-11-21 |
| US20200216568A1 (en) | 2020-07-09 |
| AU2018302110A1 (en) | 2020-02-06 |
| EP3655432A1 (en) | 2020-05-27 |
| JP2020527355A (ja) | 2020-09-10 |
| WO2019018426A1 (en) | 2019-01-24 |
| CN111094338A (zh) | 2020-05-01 |
| US20200216567A1 (en) | 2020-07-09 |
| CA3300582A1 (en) | 2026-03-02 |
| US12312417B2 (en) | 2025-05-27 |
| US11613590B2 (en) | 2023-03-28 |
| CA3070252A1 (en) | 2019-01-24 |
| US20230406960A1 (en) | 2023-12-21 |
| WO2019018428A1 (en) | 2019-01-24 |
| US20240052063A1 (en) | 2024-02-15 |
| JP7690285B2 (ja) | 2025-06-10 |
| US20250376540A1 (en) | 2025-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272643A (en) | Binders | |
| ZA201808160B (en) | Bispecific binding proteins and uses thereof | |
| SG10202107880XA (en) | Mesothelin binding proteins | |
| GB201802201D0 (en) | Binding agents | |
| EP3655432A4 (en) | BINDING PROTEINS 1 | |
| SI3723783T1 (sl) | Peptidi, ciljni na mitohondrije | |
| PT3568022T (pt) | Proteínas inseticidas | |
| SG11202001420VA (en) | Modular binding proteins | |
| IL268288A (en) | Binders | |
| DK3737402T3 (en) | Modificeret protein | |
| GB201608197D0 (en) | Novel proteins | |
| ZA201901862B (en) | Modified factor h binding protein | |
| IL304317A (en) | tgf–beta–rii binding proteins | |
| SG11202106393SA (en) | Pseudofab-based multispecific binding proteins | |
| GB2558968B (en) | G Proteins | |
| ZA202003722B (en) | Modified globin proteins | |
| IL269477A (en) | Polypeptides that bind to IL-1R-1 | |
| ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
| ZA201905544B (en) | Modified haemoglobin proteins | |
| GB201615588D0 (en) | TSLP Binding Proteins | |
| GB201614627D0 (en) | Antigen binding proteins | |
| GB201703049D0 (en) | Single-strand binding protein | |
| HK40018957A (en) | Binding proteins 1 | |
| GB201919286D0 (en) | Binding proteins | |
| IL266419A (en) | Binding peptides |